Senior Leadership Team
The mission of ALS Biopharma, LLC is to discover new therapeutics and diagnostics that will benefit humanity, using modern methods of structural biology and ADME to derisk the drug discovery process to the greatest extent possible.
Allen B. Reitz, Ph.D., Chief Executive Officer
Dr. Reitz has had >33 years of demonstrated accomplishment as a medicinal chemist in the pharmaceutical industry, including nearly 26 years with Johnson & Johnson. For 16 years at the Spring House, Pennsylvania facility of Johnson & Johnson he led the medicinal chemistry research effort in the area of the diseases of the central nervous system for both psychiatry and neurology. He is co-inventor as well as Team Leader, in most cases, for seven compounds that have entered human clinical trials. He has ca. >140 scientific publications and 60 issued U.S. patents, and is the Editor of the journals Current Topics in Medicinal Chemistry and Technology Transfer and Entrepreneurship. He has extensive experience in project and portfolio management, target validation, hit triage, hit to lead and lead optimization medicinal chemistry, eADME profiling, and preclinical candidate selection. He is also Adjunct Professor at Drexel University, College of Medicine.
Jay Wrobel, Ph.D., Vice President, Business Development
Dr. Wrobel has spent 28 years as a medicinal chemist in the pharmaceutical industry, 26 years at Wyeth (later Pfizer), with his last position as Senior Director of Medicinal Chemistry at the Collegeville, PA facility. At Wyeth he mentored and guided the efforts of 31 Ph.D./MS medicinal chemists and worked successfully with outside alliance partners. He was directly involved in bringing forward nine development track candidates (phase 0 and beyond) in a variety of therapeutic areas. He has co-authored 65 scientific publications and is an inventor on 75 issued US patents. Jay is specifically responsible for developing new collaborative research relationships and obtaining funding for early stage opportunities in drug discovery and development. Dr. Wrobel may be contacted at JWrobel@alsbiopharma.com.
Kathleen Czupich, M.B.A., Chief Financial Officer
Ms. Czupich has over 20 years of experience in business development. Prior to joining ALS Biopharma Ms. Czupich was the Chief Financial Officer of the PA Biotechnology Center, Institute for Hepatitis and Virus Research and the Hepatitis B Foundation and was point of contact for all NIH grants and other government funding totaling more than $5 million. Ms. Czupich holds a B.S. degree in Accounting from the Pennsylvania State University and an M.B.A from Lehigh University, Bethlehem, PA. Ms. Czupich's strengths are in designing financial reporting systems, managing large projects and training staff. She was the founding administrator for the Institute for Hepatitis and Virus Research and the Pennsylvania Biotech Center and was integral in all aspects of the establishment, funding and growth of those organizations. She is experienced in indirect cost requirements and negotiation. Ms. Czupich managed the financial and administrative aspects of a $7.9 million grant to construct the PBC and the resulting building project totaling more than $14 million. She was also instrumental in the negotiation, financing and purchase of the adjacent building, expanding the PBC to 115,000 square feet.